Proteasome inhibitors as anticancer agents

References

• Jang HH. Regulation of protein degradation by proteasomes in cancer. J Cancer Prev. 2018;23(4):153–161. doi: 10.15430/JCP.2018.23.4.153
   PubMed Web of Science ®Google Scholar
• Dong S, Chen H, Zhou Q, et al. Protein degradation control and regulation of bacterial survival and pathogenicity: the role of protein degradation systems in bacteria. Mol Biol Rep. 2021;48(11):7575–7585. doi: 10.1007/s11033-021-06744-9
   PubMed Web of Science ®Google Scholar
• Ignatz-Hoover JJ, Murphy EV, Driscoll JJ. Targeting proteasomes in cancer and infectious disease: a parallel strategy to Treat malignancies and microbes. Front Cell Infect Microbiol. 2022;12:925804. doi: 10.3389/fcimb.2022.925804
   PubMed Web of Science ®Google Scholar
• Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017;14(7):417–433. doi: 10.1038/nrclinonc.2016.206
   PubMed Web of Science ®Google Scholar
• Tu Y, Chen C, Pan J, et al. The ubiquitin proteasome pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis. Int J Clin Exp Pathol. 2012;5(8):726–738.
   PubMed Web of Science ®Google Scholar
• Rousseau A, Bertolotti A. Regulation of proteasome assembly and activity in health and disease. Nat Rev Mol Cell Biol. 2018;19(11):697–712. doi: 10.1038/s41580-018-0040-z
   PubMed Web of Science ®Google Scholar
• Dale B, Cheng M, Park KS, et al. Advancing targeted protein degradation for cancer therapy. Nat Rev Cancer. 2021;21(10):638–654. doi: 10.1038/s41568-021-00365-x
   PubMed Web of Science ®Google Scholar
• Schmidt M, Finley D. Regulation of proteasome activity in health and disease. Biochim Biophys Acta. 2014;1843(1):13–25. doi: 10.1016/j.bbamcr.2013.08.012
   PubMed Web of Science ®Google Scholar
• Thibaudeau TA, Smith DM, Ma Q. A practical review of proteasome pharmacology. Pharmacol Rev. 2019;71(2):170–197. doi: 10.1124/pr.117.015370
   PubMed Web of Science ®Google Scholar
• DeMartino GN, Proske RJ, Moomaw CR, et al. Identification, purification, and characterization of a PA700-dependent activator of the proteasome. J Biol Chem. 1996;271(6):3112–3118. doi: 10.1074/jbc.271.6.3112
   PubMed Web of Science ®Google Scholar
• Borissenko L, Groll M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem Rev. 2007;107(3):687–717. doi: 10.1021/cr0502504
   PubMed Web of Science ®Google Scholar
• DeMartino GN, Slaughter CA. The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem. 1999;274(32):22123–22126. doi: 10.1074/jbc.274.32.22123
   PubMed Web of Science ®Google Scholar
• Tracz M, Bialek W. Beyond K48 and K63: non-canonical protein ubiquitination. Cell Mol Biol Lett. 2021;26(1):1. doi: 10.1186/s11658-020-00245-6
   PubMed Web of Science ®Google Scholar
• Lefaki M, Papaevgeniou N, Chondrogianni N. Redox regulation of proteasome function. Redox Biol. 2017;13:452–458. doi: 10.1016/j.redox.2017.07.005
   PubMed Web of Science ®Google Scholar
• Budenholzer L, Cheng CL, Li Y, et al. Proteasome structure and assembly. J Mol Biol. 2017;429(22):3500–3524. doi: 10.1016/j.jmb.2017.05.027
   PubMed Web of Science ®Google Scholar
• Bard JAM, Goodall EA, Greene ER, et al. Structure and function of the 26S proteasome. Annu Rev Biochem. 2018;87(1):697–724. doi: 10.1146/annurev-biochem-062917-011931
   PubMedGoogle Scholar
• Structure MY. Dynamics and function of the 26S proteasome. Subcell Biochem. 2021;96:1–151.
   PubMedGoogle Scholar
• Groll M, Ditzel L, Löwe J, et al. Structure of 20S proteasome from yeast at 2.4 a resolution. Nature. 1997;386(6624):463–471. doi: 10.1038/386463a0
   PubMed Web of Science ®Google Scholar
• Schrader J, Henneberg F, Mata RA, et al. The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design. Science. 2016;353(6299):594–598. doi: 10.1126/science.aaf8993
   PubMed Web of Science ®Google Scholar
• Park JE, Miller Z, Jun Y, et al. Next-generation proteasome inhibitors for cancer therapy. Transl Res. 2018;198:1–16. doi: 10.1016/j.trsl.2018.03.002
   PubMed Web of Science ®Google Scholar
• Rabl J, Smith DM, Yu Y, et al. Mechanism of gate opening in the 20S proteasome by the proteasomal ATPases. Mol Cell. 2008;30(3):360–368. doi: 10.1016/j.molcel.2008.03.004
   PubMed Web of Science ®Google Scholar
• Voges D, Zwickl P, Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem. 1999;68(1):1015–1068. doi: 10.1146/annurev.biochem.68.1.1015
   PubMedGoogle Scholar
• Kisselev AF, Callard A, Goldberg AL. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem. 2006;281(13):8582–8590. doi: 10.1074/jbc.M509043200
   PubMed Web of Science ®Google Scholar
• Aliabadi F, Sohrabi B, Mostafavi E, et al. Ubiquitin–proteasome system and the role of its inhibitors in cancer therapy. Open Biol. 2021;11(4):200390. doi: 10.1098/rsob.200390
   PubMed Web of Science ®Google Scholar
• Fricker LD. Proteasome inhibitor drugs. Annu Rev Pharmacol Toxicol. 2020;60(1):457–476. doi: 10.1146/annurev-pharmtox-010919-023603
   PubMedGoogle Scholar
• Tsvetkov P, Adler J, Myers N, et al. Oncogenic addiction to high 26S proteasome level. Cell Death Dis. 2018;9(7):773. doi: 10.1038/s41419-018-0806-4
   PubMedGoogle Scholar
• Voorhees PM, Dees EC, O’Neil B, et al. The proteasome as a target for cancer therapy. Clin Cancer Res. 2003;9(17):6316–6325.
   PubMed Web of Science ®Google Scholar
• Voutsadakis IA. Proteasome expression and activity in cancer and cancer stem cells. Tumour Biol. 2017;39(3):1010428317692248. doi: 10.1177/1010428317692248
   Google Scholar
• Guang MHZ, Kavanagh E, Dunne L, et al. Targeting Proteotoxic stress in cancer: a review of the role that protein quality control pathways play in oncogenesis. Cancers (Basel). 2019;11(1):66. doi: 10.3390/cancers11010066
   PubMed Web of Science ®Google Scholar
• Deshaies RJ. Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy. BMC Biol. 2014;12(1):94. doi: 10.1186/s12915-014-0094-0
   PubMedGoogle Scholar
• Goldberg AL. Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans. 2007;35(Pt 1):12–17. doi: 10.1042/BST0350012
   PubMedGoogle Scholar
• Yang XF, Zhao Z-J, Liu J-J, et al. SAHA and/or MG132 reverse the aggressive phenotypes of glioma cells: an in vitro and vivo study. Oncotarget. 2017;8(2):3156–3169. doi: 10.18632/oncotarget.13680
   PubMedGoogle Scholar
• Lee HK, Park SH, Nam MJ. Proteasome inhibitor MG132 induces apoptosis in human osteosarcoma U2OS cells. Hum Exp Toxicol. 2021;40(11):1985–1997. doi: 10.1177/09603271211017972
   PubMed Web of Science ®Google Scholar
• Kim B-S, Kim CU, Kim Y-J, et al. Proteasome inhibitors can induce caspase-3 activation and apoptosis in human CML cell lines. Blood. 2004;104(11):4681. doi: 10.1182/blood.V104.11.4681.4681
   Web of Science ®Google Scholar
• Matsuo Y, Sawai H, Ochi N, et al. Proteasome inhibitor MG132 inhibits Angiogenesis in pancreatic cancer by blocking NF-κB activity. Dig Dis Sci. 2010;55(4):1167–1176. doi: 10.1007/s10620-009-0814-4
   PubMed Web of Science ®Google Scholar
• Wang X, Yu J, Liu X, et al. PSMG2-controlled proteasome-autophagy balance mediates the tolerance for MEK-targeted therapy in triple-negative breast cancer. Cell Rep Med. 2022;3(9):100741. doi: 10.1016/j.xcrm.2022.100741
   PubMedGoogle Scholar
• Deshmukh RR . Proteasome inhibition as a potential anti-breast cancer therapy: mechanisms of action and resistance-reversing strategies. Detroit (MI): Wayne State University Dissertations; 2015. https://digitalcommons.wayne.edu/oa_dissertations/1333
   Google Scholar
• Zhang Y, Shi Y, Li X, et al. Proteasome inhibitor MG132 reverses multidrug resistance of gastric cancer through enhancing apoptosis and inhibiting P-gp. Cancer Biol Ther. 2008;7(4):540–546. doi: 10.4161/cbt.7.4.5483
   PubMed Web of Science ®Google Scholar
• Xu P, Zhang Y, Ge F, et al. Modulation of tumor microenvironment to enhance radiotherapy efficacy in esophageal squamous cell carcinoma by inhibiting carbonic anhydrase IX. Front Oncol. 2021;11:637252. doi: 10.3389/fonc.2021.637252
   PubMed Web of Science ®Google Scholar
• Guo N, Peng Z, Zhang J. Proteasome inhibitor MG132 enhances sensitivity to cisplatin on ovarian carcinoma cells in vitro and in vivo. Int J Gynecol Cancer. 2016;26(5):839–844. doi: 10.1097/IGC.0000000000000703
   PubMed Web of Science ®Google Scholar
• Seo PW, Lee KY. The proteasome inhibitor MG132 sensitizes lung cancer cells to TRAIL-induced apoptosis by inhibiting NF-κB activation. trd. Tuberc Respir Dis (Seoul). 2008;65(6):476–486. doi: 10.4046/trd.2008.65.6.476
   Google Scholar
• Cheong HJ, Lee KS, Woo IS, et al. Up-regulation of the DR5 expression by proteasome inhibitor MG132 augments TRAIL-induced apoptosis in soft tissue sarcoma cell lines. Cancer Res Treat. 2011;43(2):124–130. doi: 10.4143/crt.2011.43.2.124
   PubMed Web of Science ®Google Scholar
• Li X, Pham V, Tippin M, et al. Flavokawain B targets protein neddylation for enhancing the anti-prostate cancer effect of bortezomib via Skp2 degradation. Cell Commun Signaling. 2019;17(1):25. doi: 10.1186/s12964-019-0338-2
   PubMedGoogle Scholar
• Zhang Z, Zhang S, Lin B, et al. Combined treatment of marizomib and cisplatin modulates cervical cancer growth and invasion and enhances antitumor potential in vitro and in vivo. Front Oncol. 2022;12:974573. doi: 10.3389/fonc.2022.974573
   PubMed Web of Science ®Google Scholar
• Roeten MSF, Cloos J, Jansen G, et al. Positioning of proteasome inhibitors in therapy of solid malignancies. Cancer Chemother Pharmacol. 2018;81(2):227–243. doi: 10.1007/s00280-017-3489-0
   PubMed Web of Science ®Google Scholar
• Jackson G, Einsele H, Moreau P, et al. Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. Cancer Treat Rev. 2005;31(8):591–602. doi: 10.1016/j.ctrv.2005.10.001
   PubMed Web of Science ®Google Scholar
• Reddy N, Czuczman MS. Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies. Ann Oncol. 2010;21(9):1756–1764. doi: 10.1093/annonc/mdq009
   PubMed Web of Science ®Google Scholar
• Duechler M, Linke A, Cebula B, et al. In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells. Eur J Haematol. 2005;74(5):407–417. doi: 10.1111/j.1600-0609.2004.00406.x
   PubMed Web of Science ®Google Scholar
• VELCADE FDA. Food and drug administration. 2003.
   Google Scholar
• VELCADE EMA. European Medicines Agency. 2004.
   Google Scholar
• Robak P, Robak T. Bortezomib for the treatment of hematologic malignancies: 15 Years Later. Drugs R D. 2019;19(2):73–92. doi: 10.1007/s40268-019-0269-9
   PubMed Web of Science ®Google Scholar
• NIH. A phase II study of PS-341 in patients with metastatic colorectal cancer. National Library of Medicine; 2005.
   Google Scholar
• NIH. A randomized phase II trial of PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma. National Library of Medicine; 2007.
   Google Scholar
• NIH. A phase II trial of PS-341 in combination with paclitaxel and carboplatin for metastatic adenocarcinoma of the lower esophagus, gastroesophageal junction, and Gastric Cardia. National Library of Medicine; 2008.
   Google Scholar
• Chattopadhyay N, Berger AJ, Koenig E, et al. KRAS genotype correlates with proteasome inhibitor ixazomib activity in preclinical in vivo models of colon and non-small cell lung cancer: potential role of tumor metabolism. PLoS One. 2015;10(12):e0144825. doi: 10.1371/journal.pone.0144825
   PubMed Web of Science ®Google Scholar
• Yue D, Sun X. Ixazomib promotes CHOP-dependent DR5 induction and apoptosis in colorectal cancer cells. Cancer Biol Ther. 2019;20(3):284–294. doi: 10.1080/15384047.2018.1529095
   PubMed Web of Science ®Google Scholar
• Liu W, Chen J, Tamayo AT, et al. Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. Oncotarget. 2018;9(1):346–360. doi: 10.18632/oncotarget.20378
   PubMedGoogle Scholar
• Asano T, Sato A, Okubo K. MP72-09 RITONAVIR and IXAZOMIB INHIBIT RENAL CANCER GROWTH in vitro and in vivo by INDUCING ENDOPLASMIC RETICULUM STRESS SYNERGISTICALLY. J Urol. 2018;199(4S). doi: 10.1016/j.juro.2018.02.2293
   PubMedGoogle Scholar
• Suarez-Kelly LP, Kemper GM, Duggan MC, et al. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma. Oncotarget. 2016;7(49):81172–81186. doi: 10.18632/oncotarget.12791
   PubMedGoogle Scholar
• Raedler LA. Ninlaro (ixazomib): first oral proteasome inhibitor approved for the treatment of patients with relapsed or refractory multiple myeloma. Am Health Drug Benefits. 2016;9(Spec Feature):102–105.
   PubMedGoogle Scholar
• NIH. A window study of ixazomib in untreated indolent B-NHL-current. National Library of Medicine.
   Google Scholar
• NIH. Phase II trial of ixazomib combined with gemcitabine and doxorubicin in patients with renal medullary carcinoma-current. National Library of Medicine.
   Google Scholar
• NIH. Phase I study of the combination of MLN9708 and fulvestrant in patients with advanced estrogen receptor positive breast cancer. National Library of Medicine; 2018.
   Google Scholar
• Piva R, Ruggeri B, Williams M, et al. CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood. 2008;111(5):2765–2775. doi: 10.1182/blood-2007-07-100651
   PubMed Web of Science ®Google Scholar
• Sanchez E, Li M, Li J, et al. CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma. Leuk Res. 2012;36(11):1422–1427. doi: 10.1016/j.leukres.2012.07.018
   PubMed Web of Science ®Google Scholar
• Sanchez E, Li M, Steinberg JA, et al. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan. Br J Haematol. 2010;148(4):569–581. doi: 10.1111/j.1365-2141.2009.08008.x
   PubMed Web of Science ®Google Scholar
• Rausch JL, Ali AA, Lee DM, et al. Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells. Sci Rep. 2020;10(1):5178. doi: 10.1038/s41598-020-62088-7
   PubMed Web of Science ®Google Scholar
• Li J, Zhuo J-Y, Zhou W, et al. Endoplasmic reticulum stress triggers delanzomib-induced apoptosis in HCC cells through the PERK/eIF2α/ATF4/CHOP pathway. Am J Transl Res. 2020;12(6):2875–2889.
   PubMed Web of Science ®Google Scholar
• Wang M, Liang L, Lu J, et al. Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin-induced apoptosis. Thorac Cancer. 2019;10(4):918–929. doi: 10.1111/1759-7714.13030
   PubMed Web of Science ®Google Scholar
• Guo KY, Han L, Li X, et al. Novel proteasome inhibitor delanzomib sensitizes cervical cancer cells to doxorubicin-induced apoptosis via stabilizing tumor suppressor proteins in the p53 pathway. Oncotarget. 2017;8(69):114123–114135. doi: 10.18632/oncotarget.23166
   PubMedGoogle Scholar
• Isono M, SATO A, ASANO T, et al. Delanzomib interacts with ritonavir synergistically to cause endoplasmic reticulum stress in renal cancer cells. Anticancer Res. 2018;38(6):3493–3500. doi: 10.21873/anticanres.12620
   PubMed Web of Science ®Google Scholar
• Vogl DT, Martin TG, Vij R, et al. Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. Leuk Lymphoma. 2017;58(8):1872–1879. doi: 10.1080/10428194.2016.1263842
   PubMed Web of Science ®Google Scholar
• NIH. An open-label study to determine the maximum tolerated dose and evaluate the safety and efficacy of CEP-18770 in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. National Library of Medicine; 2013.
   Google Scholar
• Gallerani E, Zucchetti M, Brunelli D, et al. A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. Eur J Cancer. 2013;49(2):290–296. doi: 10.1016/j.ejca.2012.09.009
   PubMed Web of Science ®Google Scholar
• Busonero C, Leone S, Klemm C, et al. A functional drug re-purposing screening identifies carfilzomib as a drug preventing 17β-estradiol: ERα signaling and cell proliferation in breast cancer cells. Mol Cell Endocrinol. 2018;460:229–237. doi: 10.1016/j.mce.2017.07.027
   PubMed Web of Science ®Google Scholar
• Shi Y, Yu Y, Wang Z, et al. Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells. Oncotarget. 2016;7(45):73697–73710. doi: 10.18632/oncotarget.12048
   PubMedGoogle Scholar
• Terzi H, Mustafa E, Ergul M, et al. Proteasome inhibitor carfilzomib enhances the anticancer effect of paclitaxel in MDA-MB-231 breast cancer cells. Indian J Pharm Sci. 2019;81(6):81. doi: 10.36468/pharmaceutical-sciences.616
   Web of Science ®Google Scholar
• Baker AF, Hanke NT, Sands BJ, et al. Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models. J Exp Clin Cancer Res. 2014;33(1):111. doi: 10.1186/s13046-014-0111-8
   PubMedGoogle Scholar
• Mehta A, Zhang L, Boufraqech M, et al. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer. Endocr Relat Cancer. 2015;22(3):319–329. doi: 10.1530/ERC-14-0510
   PubMed Web of Science ®Google Scholar
• Guan S, Zhao Y, Lu J, et al. Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis. Oncotarget. 2016;7(46):75914–75925. doi: 10.18632/oncotarget.12427
   PubMedGoogle Scholar
• Zang Y, Thomas SM, Chan ET, et al. The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4. Autophagy. 2012;8(12):1873–1874. doi: 10.4161/auto.22185
   PubMed Web of Science ®Google Scholar
• Zang Y, Kirk CJ, Johnson DE. Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors. Cancer Biol Ther. 2014;15(9):1142–1152. doi: 10.4161/cbt.29452
   PubMed Web of Science ®Google Scholar
• Tang W, SU G, LI J, et al. Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo. Int J Oncol. 2014;45(3):995–1010. doi: 10.3892/ijo.2014.2513
   PubMed Web of Science ®Google Scholar
• FDA, KYPROLIS. 2012. Food and Drug Administration.
   Google Scholar
• EMA, KYPROLIS. 2015. European Medicines Agency.
   Google Scholar
• Burke MJ, Ziegler DS, Bautista F, et al. Phase 1b study of carfilzomib with induction chemotherapy in pediatric relapsed/refractory acute lymphoblastic leukemia. Pediatr Blood Cancer. 2022;69(12):e29999. doi: 10.1002/pbc.29999
   PubMed Web of Science ®Google Scholar
• Hurchla MA, Garcia-Gomez A, Hornick MC, et al. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia. 2013;27(2):430–440. doi: 10.1038/leu.2012.183
   PubMed Web of Science ®Google Scholar
• Sanchez E, Mingjie L, Abigail G, et al. Effects of oprozomib in combination with pomalidomide and/or dexamethasone on human multiple myeloma tumors growing in SCID mice. Blood. 2015;126(23):5349. doi: 10.1182/blood.V126.23.5349.5349
   Web of Science ®Google Scholar
• Shi Y, Bieerkehazhi S, Ma H. Next-generation proteasome inhibitor oprozomib enhances sensitivity to doxorubicin in triple-negative breast cancer cells. Int J Clin Exp Pathol. 2018;11(5):2347–2355.
   PubMed Web of Science ®Google Scholar
• Vandewynckel YP, Coucke C, Laukens D, et al. Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma. Oncotarget. 2016;7(23):34988–35000. doi: 10.18632/oncotarget.9222
   PubMedGoogle Scholar
• Zhu H, Wang T, Xin Z, et al. An oral second-generation proteasome inhibitor oprozomib significantly inhibits lung cancer in a p53 independent manner in vitro. Acta Biochim Biophys Sin (Shanghai). 2019;51(10):1034–1040. doi: 10.1093/abbs/gmz093
   PubMed Web of Science ®Google Scholar
• Caputi FF, Di Cesare Mannelli L, Rullo L, et al. The active second-generation proteasome inhibitor oprozomib reverts the oxaliplatin-induced neuropathy symptoms. Biochem Pharmacol. 2020;182:114255. doi: 10.1016/j.bcp.2020.114255
   PubMed Web of Science ®Google Scholar
• Kazuki O, ISONO M, ASANO T, et al. Ubiquitin-proteasome system is a promising target for killing cisplatin-resistant bladder cancer cells. Anticancer Res. 2021;41(6):2901. doi: 10.21873/anticanres.15072
   PubMed Web of Science ®Google Scholar
• Hungria VTM, Crusoé EDQ, Bittencourt RI, et al. New proteasome inhibitors in the treatment of multiple myeloma. Hematol Transfus Cell Ther. 2019;41(1):76–83. doi: 10.1016/j.htct.2018.07.003
   PubMedGoogle Scholar
• Boccellato C, Kolbe E, Peters N, et al. Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist. Cell Death Dis. 2021;12(7):647. doi: 10.1038/s41419-021-03927-x
   PubMed Web of Science ®Google Scholar
• Raninga PV, Lee A, Sinha D, et al. Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition. Theranostics. 2020;10(12):5259–5275. doi: 10.7150/thno.42705
   PubMed Web of Science ®Google Scholar
• Xu J, Liao M, Chen Y, et al. Novel fabrication of marizomib-loaded chitosan-coated hydroxyapatite nanocarriers as a promising system for effective treatment of ovarian cancer. Mater Res Express. 2022;9(3):9. doi: 10.1088/2053-1591/ac5077
   Web of Science ®Google Scholar
• Roth P, Reijneveld J, Gorlia T, et al. P14.124 EORTC 1709/CCTG CE.8: a phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma, in Neuro Oncol. 2019. © The Author(s). 2019;21(Supplement_3):iii98. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: [email protected]. doi: 10.1093/neuonc/noz126.359
   Google Scholar
• NIH. Phase 2 clinical trial of NPI-0052 in patients with relapsed or relapsed/refractory multiple myeloma, in identifier: nCT00461045. National Library of Medicine; 2014.
   Google Scholar
• Millward M, Price T, Townsend A, et al. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest New Drugs. 2012;30(6):2303–2317. doi: 10.1007/s10637-011-9766-6
   PubMed Web of Science ®Google Scholar
• NIH. NPI-0052 and vorinostat in patients with non-small cell lung cancer, pancreatic cancer, melanoma or lymphoma. National Library of Medicine; 2010.
   Google Scholar
• Kisselev AF, van der Linden WA, Overkleeft HS, et al. Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol. 2012;19(1):99–115. doi: 10.1016/j.chembiol.2012.01.003
   PubMed Web of Science ®Google Scholar
• Lynas JF, Harriott P, Healy A, et al. Inhibitors of the chymotrypsin-like activity of proteasome based on di- and tri-peptidyl alpha-keto aldehydes (glyoxals). Bioorg Med Chem Lett. 1998;8(4):373–378. doi: 10.1016/S0960-894X(98)00030-4
   PubMed Web of Science ®Google Scholar
• Vinitsky A, Michaud C, Powers JC, et al. Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry. 1992;31(39):9421–9428. doi: 10.1021/bi00154a014
   PubMed Web of Science ®Google Scholar
• Stein RL, MA YT, Brand S. inventor; ProScript, Inc. assignee. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein United States patent US 5,693,617. 1997 Dec 2.
   Google Scholar
• Beck P, Dubiella C, Groll M. Covalent and non-covalent reversible proteasome inhibition. Biol Chem. 2012;393(10):1101–1120. doi: 10.1515/hsz-2012-0212
   PubMed Web of Science ®Google Scholar
• Han YH, Moon HJ, You BR, et al. The effect of MG132, a proteasome inhibitor on HeLa cells in relation to cell growth, reactive oxygen species and GSH. Oncol Rep. 2009;22(1):215–221. doi: 10.3892/or_00000427
   PubMed Web of Science ®Google Scholar
• Kim YM, Kim HJ. Proteasome inhibitor MG132 is toxic and inhibits the proliferation of rat neural stem cells but increases BDNF expression to protect neurons. Biomolecules. 2020;10(11):1507. doi: 10.3390/biom10111507
   PubMed Web of Science ®Google Scholar
• Park WH, Kim SH. MG132, a proteasome inhibitor, induces human pulmonary fibroblast cell death via increasing ROS levels and GSH depletion. Oncol Rep. 2012;27(4):1284–1291. doi: 10.3892/or.2012.1642
   PubMed Web of Science ®Google Scholar
• Goldberg AL. Development of proteasome inhibitors as research tools and cancer drugs. J Cell Bio. 2012;199(4):583–588. doi: 10.1083/jcb.201210077
   PubMed Web of Science ®Google Scholar
• Guo N, Peng Z. MG132, a proteasome inhibitor, induces apoptosis in tumor cells. Asia Pac J Clin Oncol. 2013;9(1):6–11. doi: 10.1111/j.1743-7563.2012.01535.x
   PubMed Web of Science ®Google Scholar
• Kisselev AF. Site-specific proteasome inhibitors. Biomolecules. 2021;12(1):54. doi: 10.3390/biom12010054
   PubMed Web of Science ®Google Scholar
• Braun HA, Umbreen S, Groll M, et al. Tripeptide mimetics inhibit the 20 S proteasome by covalent bonding to the active threonines. J Biol Chem. 2005;280(31):28394–28401. doi: 10.1074/jbc.M502453200
   PubMed Web of Science ®Google Scholar
• Boris Schmidt B, Umbreen S, Braun H, et al. Technische Universität, Charité-Universitätsmedizin Berlin assignee. MIMETIC PEPTIDES AND THE USE THEREOF IN THE FORM OF 20S, 26S AND MMUNOPROTEASOME INHIBITORS. United States Patent US 8,835,392. inventor. 2014 Sep 16.
   Google Scholar
• Zang M, Li Z, Liu L, et al. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma. Cancer Lett. 2015;366(2):173–181. doi: 10.1016/j.canlet.2015.06.011
   PubMed Web of Science ®Google Scholar
• Sterz J, Jakob C, Kuckelkorn U, et al. BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma. Eur J Haematol. 2010;85(2):99–107. doi: 10.1111/j.1600-0609.2010.01450.x
   PubMed Web of Science ®Google Scholar
• Mlynarczuk-Bialy I, Doeppner TR, Golab J, et al. Biodistribution and efficacy studies of the proteasome inhibitor BSc2118 in a mouse melanoma Model. Transl Oncol. 2014;7(5):570–579. doi: 10.1016/j.tranon.2014.07.002
   PubMed Web of Science ®Google Scholar
• Młynarczuk-Biały I, Roeckmann H, Kuckelkorn U, et al. Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells. Cancer Res. 2006;66(15):7598–7605. doi: 10.1158/0008-5472.CAN-05-2614
   PubMed Web of Science ®Google Scholar
• Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol. 2001;8(8):739–758. doi: 10.1016/S1074-5521(01)00056-4
   PubMed Web of Science ®Google Scholar
• Matteson DS, Ray R. Directed chiral synthesis with pinanediol boronic esters J. Am Chem Soc. 1980;102(25):7590. doi: 10.1021/ja00545a046
   Web of Science ®Google Scholar
• Appavu R, Mohan D. Bortezomib in anti-cancer activity: a potential drug. Glob J Cancer Ther. 2016;2(1):005–008. doi: 10.17352/gjct.000007
   Google Scholar
• Cusack JC. Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev. 2003;29(1):21–31. doi: 10.1016/S0305-7372(03)00079-3
   PubMedGoogle Scholar
• Dou QP, Zonder JA. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. Curr Cancer Drug Targets. 2014;14(6):517–536. doi: 10.2174/1568009614666140804154511
   PubMed Web of Science ®Google Scholar
• Lü S, Wang J. The resistance mechanisms of proteasome inhibitor bortezomib. Biomark Res. 2013;1(1):13. doi: 10.1186/2050-7771-1-13
   PubMedGoogle Scholar
• Lin G, Zhan W, Zhang H, et al. Inventor; UNIV CORNELL assegnee. Artemisinin-proteasome inhibitor conjugates and their use in the treatment of disease. WO2022159581. 2022 Jul 28.
   Google Scholar
• Demario MD, Friess T, Ruefli-Brasse AA. inventor; Hoffmann-La Roche Inc. assignee. Combination theraphy with a bet inhibitor and a proteasome inhibitor. United States US2021002309. 2021 Jan 28.
   Google Scholar
• Kerckhove N, Collin A, Condé S, et al. Long term effects, pathophysiological mechanisms, and risk factors of chemotherapy induced peripheral neuropathies: a comprehensive literature review. Front Pharmacol. 2017;8:86. doi: 10.3389/fphar.2017.00086
   PubMed Web of Science ®Google Scholar
• TOURMALINE-MM1 Study Group, Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621–1634.
   PubMed Web of Science ®Google Scholar
• Muz B, Ghazarian RN, Ou M, et al. Spotlight on ixazomib: potential in the treatment of multiple myeloma. Drug Des Devel Ther. 2016;10:217–226. doi: 10.2147/DDDT.S93602
   PubMed Web of Science ®Google Scholar
• Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther. 2011;10(11):2034–2042. doi: 10.1158/1535-7163.MCT-11-0433
   PubMed Web of Science ®Google Scholar
• Hao F, Yi Z, Xuben H, et al. Inventor; UNIV SHANDONG assignee. Histone deacetylase, and proteasome dual-target inhibitor, preparation method therefor and application thereof. W O2021115188. 2021 Jun 17.
   Google Scholar
• Yan G, Zhang H, Zhu W, et al. GUANGZHOU VIROTECH PHARMACEUTICAL CO assignee. Use of preteasome inhibtior and alphavirus in preparation of anti-tumor medicament. United States, US20210228660. inventor. 2021 Jul 29.
   Google Scholar
• Lynas JF, Harriott P, Healy A, et al. Inhibitors of the chymotrypsin-like activity of proteasome based on di- and tri-peptidyl α-keto aldehydes (glyoxals). Bioorg Med Chem Lett. 1998;8(4):373–378. doi: 10.1016/S0960-894X(98)00030-4
   PubMed Web of Science ®Google Scholar
• Walker B, McCarthy N, Healy A, et al. Peptide glyoxals: a novel class of inhibitor for serine and cysteine proteinases. Biochem J. 1993;293(2):321. doi: 10.1042/bj2930321
   PubMedGoogle Scholar
• Crawford LJ, Walker B, Ovaa H, et al. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res. 2006;66(12):6379–6386. doi: 10.1158/0008-5472.CAN-06-0605
   PubMed Web of Science ®Google Scholar
• Gräwert MA, Gallastegui N, Stein M, et al. Elucidation of the α-keto-aldehyde binding mechanism: a lead structure motif for proteasome inhibition. Angew Chem Int Ed Engl. 2011;50(2):542–544. doi: 10.1002/anie.201005488
   PubMed Web of Science ®Google Scholar
• Meng L, Mohan R, Kwok BH, et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A. 1999;96(18):10403–10408. doi: 10.1073/pnas.96.18.10403
   PubMed Web of Science ®Google Scholar
• Kim KB, Crews CM. From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes. Nat Prod Rep. 2013;30(5):600–604. doi: 10.1039/c3np20126k
   PubMed Web of Science ®Google Scholar
• Meng L, Mohan R, Kwok BH, et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Natl Acad Sci USA. 1999;96(18):10403–10408. doi: 10.1073/pnas.96.18.10403
   PubMed Web of Science ®Google Scholar
• Groll M, Kim KB, Kairies N, et al. Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis for selectivity of alphaP, betaP-epoxyketone proteasome inhibitors. J Am Chem Soc. 2000;122:1237–1238. doi: 10.1021/ja993588m
   Web of Science ®Google Scholar
• Sugumar D, Keller J, Vij R. Targeted treatments for multiple myeloma: specific role of carfilzomib. Pharm Genomics Pers Med. 2015;8:23–33. doi: 10.2147/PGPM.S39085
   PubMed Web of Science ®Google Scholar
• Smyth MS, Laidig GJ, Borchardt RT, et al. inventor . Proteolix Inc. Compounds For Enzyme Inhibition. United States US20050245435. 2005 Nov 3.
   Google Scholar
• Zhou Q, Liang J, Yang T, et al. Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer. EMBO Mol Med. 2022;14(1):e14502. doi: 10.15252/emmm.202114502
   PubMed Web of Science ®Google Scholar
• Laubach JP, Mitsiades CS, Roccaro AM, et al. Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia. Leuk Lymphoma. 2009;50(5):694–702. doi: 10.1080/10428190902866732
   PubMed Web of Science ®Google Scholar
• Zhou HJ, Laidig GJ, Shenk KD, et al. inventor. Proteolix Inc. Assignee. Compounds For Enzyme Inhibition. WO2008140782. 2008 Nov 20.
   Google Scholar
• Inventor KK. UNIV KENTUCKY RES FOUND assegnee. Pro Inh. United States US11578101. 2023 Feb 14.
   Google Scholar
• Feling RH, Buchanan GO, Mincer TJ, et al. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew Chem Int Ed Engl. 2003;42(3):355–357. doi: 10.1002/anie.200390115
   PubMed Web of Science ®Google Scholar
• Maldonado LA, Fenical W, Jensen PR, et al. Salinispora arenicola gen. nov., sp. nov. And Salinispora tropica sp. nov., obligate marine actinomycetes belonging to the family micromonosporaceae. Int J Syst Evol Microbiol. 2005;55(Pt 5):1759–1766. doi: 10.1099/ijs.0.63625-0
   PubMedGoogle Scholar
• Chauhan D, Catley L, Li G, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell. 2005;8(5):407–419. doi: 10.1016/j.ccr.2005.10.013
   PubMed Web of Science ®Google Scholar
• Groll M, McArthur KA, Macherla VR, et al. Snapshots of the fluorosalinosporamide/20S complex offer mechanistic insights for fine tuning proteasome inhibition. J Med Chem. 2009;52(17):5420–5428. doi: 10.1021/jm900559x
   PubMed Web of Science ®Google Scholar
• Groll M, Huber R, Potts BCM. Crystal structures of Salinosporamide a (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of β-lactone ring Opening and a mechanism for irreversible binding. J Am Chem Soc. 2006;128(15):5136–5141. doi: 10.1021/ja058320b
   PubMed Web of Science ®Google Scholar
• Trika M, Levin N, Winograd B. Celgene international II sàrl assignee. Use of a proteasome inhibitor for the treatment of central nervous system (CNS) cancers. Unites States US20200085789. inventor. 2020 Mar 19.
   Google Scholar
• Tello-Aburto R, Rogelj S, Hallada L, et al. Inventor; NEW MEXICO TECH UNIV RESEARCH PARK CORPORATION assegnee. Proteasome Inhibitors. United State US11396497. 2022 Jul 26.
   Google Scholar